Andrea DeCensi
Italian oncologist who led TAM-01, the trial that showed a low dose of tamoxifen halves recurrence after non-invasive breast cancer with fewer side effects than the standard dose.
Overview
Andrea DeCensi is a medical oncologist at Galliera Hospital in Genoa who has spent his career on breast cancer prevention. He was first author of the 2019 Journal of Clinical Oncology report of TAM-01, an Italian trial in which tamoxifen at 5 mg a day for three years reduced recurrence and new breast cancers after ductal carcinoma in situ and other non-invasive lesions, with a toxicity profile little different from placebo. Low-dose tamoxifen is now an option in guidelines for risk reduction.
Similar pages
not linked directly; found by shared links- PersonRashmi K. Murthy
Shares Breast cancer (all types) and the tags breast, trialist.
- PersonE. Shelley Hwang
Shares Ductal carcinoma in situ (DCIS), Breast cancer (all types) and the tags breast, trialist.
- PersonGabriel N. Hortobagyi
Shares the tags breast, trialist.
- PersonStephen Johnston
Shares the tags breast, trialist.
- PersonMark E. Robson
Shares Breast cancer (all types) and the tags breast, trialist.
- PersonJosé Baselga
Shares Breast cancer (all types) and the tags breast, trialist.
- PersonRupert Bartsch
Shares Breast cancer (all types) and the tags breast, trialist.
- PersonAditya Bardia
Shares the tags breast, trialist.